Americas IBS Treatment Market Scenario
Irritable bowel syndrome (IBS) is a common ailment that affects the large intestine. Symptoms of IBS include cramping, abdominal pain, bloating, gas, diarrhea and constipation. Diagnosis of irritable bowel syndrome is done by tests such as blood tests, stool tests, endoscopic procedures and external imaging procedures whereas the treatment includes relieving the patient from the symptoms and improving the quality of life.
The Americas IBS treatment market is expected to grow at a CAGR of 9.3% during the forecast period 2017-2023. The major growth drivers for the irritable bowel syndrome treatment market are expected launches of various pipeline drugs for the treatment during the forecast period. Increasing prevalence of gastrointestinal diseases and disorder, unhealthy diet, anxiety, and changing lifestyle in Americas also fuel this market. According to statistics published by the U.S. Food and Drug Administration (FDA), irritable bowel syndrome (IBS) is an often-misunderstood condition that affects about 15.3 million people in the United States. However, lack of specific treatment which treats all the symptoms of this disorder may restrain the growth of this market. Additionally, higher competition among the key players related to pricing is predicted to hamper growth of this market.
According to National Center for Biotechnology Information, Irritable bowel syndrome has a prevalence of 1% to 20% worldwide, although up to 75% affected individuals never seek care. In North America, irritable bowel syndrome prevalence is 5% to 10%, affecting any age, and is 3 to 4 times more common in women.
Request Free Sample at https://www.marketresearchfuture.com/sample_request/5555
Americas IBS Treatment Market –Competitive Landscape
The Americas IBS treatment market is observed to be growing upwards due to key players such as Allergan Plc (Ireland), Sucampo Pharmaceuticals, Inc. (U.S.), Ironwood Pharmaceuticals, Inc. (U.S.), Astellas Pharma Inc. (Japan), Bausch Health Companies Inc. (Canada), Abbott Laboratories (U.S.), Synergy Pharmaceuticals, Inc. (U.S.), Ardelyx, Inc. (U.S.), Nestlé (Switzerland), Sebela Pharmaceuticals (Ireland), Probi (Sweden), Alfasigma S.p.A. (Italy), RedHill (Israel), AstraZeneca (U.K), Ipsen Pharma (France), Novartis AG (Switzerland), Takeda Pharmaceutical Company Ltd. (Japan), Synthetic Biologics, Inc. (U.S.), Protagonist Therapeutics Inc. (U.S.), Pfizer Inc. (U.S.), Lexicon Pharmaceuticals, Inc. (U.S.), Innovate Biopharmaceuticals (U.S.), 4D pharma plc (U.K)..
Americas IBS Treatment Market Segmentation
The Americas IBS treatment market is segmented on the basis of types, drugs type, and end user. On the basis the types, it is segmented into IBS-D, IBS-C, IBS-M. On the basis of the drug type, it is segmented into lubiprostone, linaclotide, eluxadoline, rifaximin, alosetron, and others. On the basis of the end users, it is segmented into hospitals, clinics, and research laboratories.
The well-established market players are involved in strategic partnerships and collaborations and product updates to gain competitive advantage in this market.
In May 2018, Allergan Plc, a leading global pharmaceutical company, and Ironwood Pharmaceuticals, Inc., a commercial biotech company, launched an interactive digital destination who may be suffering from IBS-D, IBS-C or CIC. The name of this website is AboutYourGut.com.
In January 2018, Ardelyx, Inc. announced that the company successfully completed the safety extension portion of its Phase 3 T3MPO program, designed to support the registration of tenapanor for the treatment of patients with irritable bowel syndrome with constipation (IBS-C).
In January 2018, Synergy Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies announced that the U.S. Food and Drug Administration (FDA) has approved TRULANCE (plecanatide) 3 mg tablet for the once-daily treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
In October 2016, Nestlé introduces ProNourish, the first nationally distributed product of its kind, designed and marketed specifically for people with digestive sensitivities. ProNourish drink is a nutritional drink that helps make following a low FODMAP diet. FODMAP is an acronym for Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols, which classifies specific types of short-chain carbohydrates that can be poorly absorbed in the small intestine, resulting in severe abdominal pain, bloating, constipation and/or diarrhea in some people.
In May 2015, Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals Inc.) announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., had received approval from the U.S. Food and Drug Administration (FDA) for Xifaxan 550 mg for the treatment of IBS-D in adults.
Americas IBS Treatment Market Regional Analysis
The Americas region is divided into North America and South America.
North America holds the largest market of IBS treatment due to the well-developed healthcare infrastructure, government support, several research and development programs, widespread awareness about irritable bowel syndrome and presence of clinical laboratories.
Moreover, presence of strong economic condition, and focus of research institutions on updating technology for new irritable bowel syndrome treatments boost the growth of market in this region. Also, the countries in this region have various companies which are involved in the IBS treatment business.
TABLE OF CONTENTS
1 Report Prologue$ 1,350.00
2 Market Introduction$ 0.00
2.1 Scope Of Study 11
2.2 Research Objective 11
2.3 Assumptions & Limitations 11
2.3.1 Assumptions 11
2.3.2 Limitations 11
2.4 Market Structure 12
3 Research Methodology$ 0.00
3.1.1 Primary Research Methodology 14
3.1.2 Data Points Received From The Doctors/ Gastrologist: 14
3.1.3 Data Points Received From The Manufacturer/ Pharmaceutical Companies: 15
3.1.4 Data Points Received From Hospitals, Clinics: 15
3.1.5 Secondary Research Methodology 17
3.1.6 Market Share Analysis 19
3.1.7 Trade Analysis 19
3.1.8 Market Pricing Approach 19
4 Market Dynamics$ 950.00
4.1 Introduction 20
4.2 Drivers 21
4.2.1 Increasing Prevalence Of Anxiety (Impact Weightage: 37%) 21
4.2.2 Strong Clinical Pipeline (Impact Weightage: 35%) 22
4.2.3 Increasing Prevalence Of Depression (Impact Weightage: 28%) 23
4.3 Restraints 24
4.3.1 Strict FDA Regulations (Impact Weightage: 60%) 24
4.3.2 Unsatisfactory Effectiveness Of The Treatment (Impact Weightage: 40%) 25
4.4 Opportunity 26
4.5 Mega Trends 27
4.6 Macroeconomic Indicators 28
5 Market Factor Analysis
To view the full report, visit at https://www.marketresearchfuture.com/reports/ibs-treatment-market-5555
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
+1 646 845 9312